Identify immunotherapy biomarkers non-invasively with massively scaled proteomics |
| Circulating protein biomarkers are a promising avenue for predicting patient response to cancer immunotherapies. The SomaScan® Assay |
| processes 7,000 blood-based protein measurements simultaneously. Learn how to apply the world’s largest protein assay to immuno-oncology procedures in our case study, "Circulating protein biomarkers are a promising avenue for predicting patient response to cancer immunotherapies." |
Explore the SomaScan® Platform The SomaScan® Platform is your single platform for discovery, validation, and delivery. Using slow off-rate modified aptamers (called SOMAmer® reagents) the SomaScan® Assay provides 7,000 highly reproducible measurements of circulating proteins from a single sample of plasma, serum, or urine. |
Interested in the SomaScan® Assay? |
| © 2022 SomaLogic, Inc., all rights reserved; SomaLogic®, SOMAmer®, SomaScan®, SomaSignal™ and associated logo are trademarks owned by SomaLogic, Inc. Tests are indicated for Research Use Only (RUO) and have not been approved by the FDA. |
|
